Neurolutions

Stroke survivors are regaining arm
function with IpsiHand^TM

IpsiHand™ is an FDA-cleared non-invasive device for rehabilitation of upper extremity motor function after stroke.

About Neurolutions

Neurolutions is a medical technology company dedicated to transforming the lives of patients suffering from neurological conditions. Our mission is to develop innovative solutions that address the unmet needs of patients, and we are focused on advancing the field of neurorehabilitation through cutting-edge research and development.

About the IpsiHand

Our flagship product, the IpsiHand device, is a breakthrough in neurorehabilitation that uses brain-computer interface technology to help patients regain hand function after stroke or other brain injuries. The IpsiHand device has been clinically validated and has received FDA clearance for use in the United States. At Neurolutions, we are committed to improving patient outcomes and providing exceptional customer service to our clients. We are a team of passionate individuals who share a common goal of making a difference in the lives of patients. If you are looking for a challenging and rewarding career in the medical technology industry.

OUR TEAM JOIN OUR TEAM

IpsiHand is FDA Cleared - via De Novo

SBIR Awarded $2M to Neurolutions

First clinical trial complete. Published on Cover of Stroke

Work Towards Independence. Approximately 300,000 Americans each year suffer from post-stroke hemiparesis.

FDA Granted IpsiHand as a "Breakthrough Medical Technology"

First prescriptive orders for private pay home patients received

Neurolutions Awarded California Life Science Medical Device of the year

2022 - IpsiHand induces changes in brain (Published)

About Neurolutions

About the IpsiHand

OUR TEAM JOIN OUR TEAM

Executive Team

LEO PETROSSIAN

Chief Executive Officer, Director

Javad Seyedzadeh

Chief Operating Officer

Andy Schultz

Chief Commercial Officer

Eric Leuthardt

Founder, CSO, Director

Lisa Garrett

Chief Financial Officer

Calvin Portley

Chief Business Officer

Board of Directors

Fred Khosravi

Chairman of the Board

Amar Sawhney

Board Member

William Tai

Board Member

Stavros Vizirgianakis

Board Member

IpsiHand is FDA Cleared - via De Novo

SBIR Awarded $2M to Neurolutions

First clinical trial complete. Published on Cover of Stroke

Work Towards Independence. Approximately 300,000 Americans each year suffer from post-stroke hemiparesis.

FDA Granted IpsiHand as a "Breakthrough Medical Technology"

First prescriptive orders for private pay home patients received

Neurolutions Awarded California Life Science Medical Device of the year

2022 - IpsiHand induces changes in brain (Published)

Leo Petrossian

Leo Petrossian is the current Chief Executive Officer of Neurolutions, Inc. He is an experienced nanotechnologist searching for challenging opportunities in biotechnology and medical device entre- and intrapreneurship. Previously he co-founded Neural Analytics and is also the CEO of Nile AI, Inc.

Dr. Petrossian earned his MBA from the UCLA Anderson School of Management in 2014 and earned his Ph.D. & MS in Biomolecular Nanotechnology & Solid-State Device Physics as an NSF IGERT fellow at Arizona State University in 2007. He also holds a double B.S. in Electrical Engineering & Biomedical Engineering from California State University, Long Beach.

Javad Seyedzadeh

Javad is a Business Advisor, Corporate Officer, and Senior Executive with an impressive 35-year track record in healthcare leadership. Specializing in imaging, in vitro, and in vivo industries, he has demonstrated unparalleled expertise in Quality Assurance, Regulatory Affairs, and overall operations on a global scale, including North America, Europe, Latin America, and Asia. His strong business acumen and strategic leadership have been pivotal in navigating organizations through complex business environments worldwide. Javad has worked with companies of all sizes—from startups to Fortune 500s—managing diverse teams and cultures with finesse. In his role as Senior Vice President of Global Quality Assurance and Regulatory Affairs at Gambro, he not only enhanced quality systems but also played a key role in business strategy, contributing to the company's successful acquisition by Baxter. His extensive experience also includes tenures at Toshiba Medical Systems, Bayer Healthcare, Siemens Healthcare, and NovaSignal, where he was the Chief of Quality Assurance and Regulatory Affairs. Javad's business-oriented approach extends to product development and operational excellence. He has been instrumental in streamlining processes, reducing product costs, and implementing efficient organizational designs. His leadership has been crucial in driving product development strategies that align with regulatory compliance and market needs.

Andy Schultz

Andy Schultz is the Chief Commercial Officer of Neurolutions, Inc. Prior to joining Neurolutions, he was SVP of Revenue and Operations at Candid, a disruptor in the orthodontic clear aligner space. Andy spent nearly 5 years at Candid leading and scaling through periods of high growth and a major DTC to B2B business pivot. Prior to Candid, Andy held the title of Vice President Customer Experience and Planning at Scotts Miracle-Gro. Over 13 years there he held various leadership roles in sales, operations, strategy and supply chain. Prior to that time, Andy was a First Officer for Northwest Airlink. He served 8 years in the US Navy aboard the USS Enterprise and as a part of the Blue Angels Flight Demonstration Squadron. Andy graduated from Embry-Riddle Aeronautical University.

Eric Leuthardt, Founder

Eric C. Leuthardt, M.D. is a highly regarded neurosurgeon and professor at Washington University in St. Louis. He holds positions in several departments, including Neurological Surgery, Neuroscience, Biomedical Engineering, Mechanical Engineering, and Material Sciences, and serves as the Chief of the Division of Neurotechnology. Leuthardt is known for his innovative research in the field of neuroprosthetics, neurotechnologies, advanced brain imaging, and neurosurgical devices. His work has earned him recognition as a pioneer in applied neuroscience and he has over 1800 patents filed with the US Patent and Trademark Office for various medical devices and brain-computer interface technologies. In addition to his academic and research achievements. He is also a successful entrepreneur, having founded eight startup companies. He is an Emmy Award-winning playwright and the author of two fiction novels.

Lisa Garrett

Lisa Garrett joined Neurolutions in March 2023 and brings over 20 years experience in medical technology companies. Most recently Lisa was the CFO at Cardiva Medical until its acquisition by Haemonetics in 2021. Previously she served as CFO at ForSight Vision5, Inc., a pharmaceutical research company subsequently acquired by Allergan. Prior to ForSight Vision5, Lisa was the CFO at Corventis, Inc., a wearable arrhythmia sensor company acquired by Medtronic in 2014. Lisa also served in various financial roles at Guidant Corporation, Sybase and Eli Lilly. Lisa currently sits on the board of Channel Medsystems, a medical device company focused on women's health. Lisa earned a B.B.S. in Accounting and an M.B.A from Indiana University.

Calvin Portley

Calvin Portley has extensive work experience in various roles and industries with much of his time spent in healthcare technology commercialization. Calvin is the Chief Business Officer at Neurolutions, a position he has held since May 2020. Prior to that, he worked as a Venture Partner at Dangerous Ventures and the Managing Partner at Avon Growth Management, a lower middle market acquisition firm. Before that, he worked in various marketing and sales leadership positions at Doctor On Demand, Beckman Coulter, Johnson & Johnson, Alcon (a Novartis company), and The Kraft Heinz Company. Calvin Portley completed his Master of Business Administration (M.B.A.) degree from the UCLA Anderson School of Management in 2014 and obtained his Bachelor of Business Administration (B.B.A) in Marketing from The University of Texas at Arlington in 2003.

Fred Khosravi

Fred Khosravi is a Silicon Valley medical device entrepreneur with over 30 years of experience in medical technology, including management and executive positions in both large and small enterprises. He has co-founded Incept LLC and serves as its managing director, focusing on technology innovation and entrepreneurship in the life-sciences field and occasionally extending to information technology. Fred is credited as an inventor or co-inventor on over 200 patents and patent applications globally, holds degrees in mechanical engineering from Tennessee Tech University, and is involved in various organizations such as the Center for Strategic and International Studies, Spirit of America, and Technology for America.

Amar Sawhney

Amarpreet Sawhney is the President and CEO of Ocular Therapeutix, a company that specializes in ophthalmic surgical wound management and drug delivery. Before that, he founded and led Confluent Surgical, a biosurgery company that was acquired by Covidien. He was also the Chairman of MarketRx, a pharmaceutical marketing and sales analytics provider that was acquired by Cognizant. Dr. Sawhney has founded and is a member of the board of several companies, including Ostial Corp., TiE Boston, Ocular Therapeutix, Augmenix, and Incept LLC. He has also received numerous awards, including the MassDevice "Five Most Innovative Medical Device CEOs" award and the MIT Global Indus Technovators Award. Dr. Sawhney has a Ph.D. and M.S. in Chemical Engineering from the University of Texas at Austin and a B.Tech. in Chemical Engineering from IIT Delhi.

William Tai

William Tai is a successful entrepreneur and investor with over 30 years of experience in the technology industry. He is the Founder and Managing Partner of Amed Ventures, a San Francisco Bay Area-based venture capital fund focused on Medical Device and Medical Technologies investments. He is also the former VP of Business Development at CTBC Bank Corp. William has earned a Bachelor's Degree in Finance from National Chengchi University and an MBA from Baruch College.

Stavros Vizirgianakis

Stavros G. Vizirgianakis was the former Chief Executive Officer of Misonix (MSON) from 2016- 2021. He has a distinguished career in the medical devices field having worked for United States Surgical Corporation as director of sales for sub-Saharan Africa and later Tyco Healthcare in the capacity of General Manager South Africa. In 2006, Vizirgianakis co-founded Surgical Innovations, one of the largest privately owned medical device distributors in the African region which later became part of the Ascendis Health group.

He also served on the boards of Tenaxis Medical and Bioventus. Current board positions include Tally Surgical and Theragenics. He is a strategic investor and advisor to numerous startups and established companies in the medical device field. Vizirgianakis has a Degree in Commerce from the University of South Africa.